This food company 'stands out as a beneficiary of GLP-1 adoption' - UBS
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Help Patients Prevent Weight Gain After Stopping GLP-1sCan your patient keep the weight off without the medication? Here are expert-backed ways to help them try.
Read more »
Amid Global GLP-1 Shortages, Doctors Prioritize PatientsSome governments are asking clinicians to reserve prescriptions for those with type 2 diabetes.
Read more »
AI Identifies Two Natural Bioactive GLP-1 CompoundsTwo bioactive, natural-derived compounds, which show activity at the GLP-1R site, may be orally administered with fewer side effects than their pharmaceutical counterparts.
Read more »
Gaps Found in Appropriate SGLT2, GLP-1 PrescribingA trio of new studies showed that SGLT2 inhibitors and GLP-1 agonists are often not prescribed or accessible to people who could benefit from them.
Read more »
Restrictions Eased on Bariatric Surgery Due to GLP-1 CostsSome insurers are easing restrictions to the procedures amid concern about the potential long-term costs of the GLP-1 drugs.
Read more »
How these weight loss drugs offer benefits beyond the scaleGLP-1 receptor agonist drugs named the 2023 Breakthrough of the Year
Read more »